Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
@brewsky I agree. This company should have been private until it reached clinical POC. LSE does not value pre-revenue businesses. Why did you invest in Hemo if you think this way?
I do not agree with you assessment of CBR as BS. Dr. Sandler consistently talks about it as a very valuable platform that needs to be developed and protected. Unless he bluntly lies (that would be fraud!), there is no reason to call CBR BS.
I looked at their announcements over the last couple of months and see that they were pretty good telling the market about key stages of their product candidate developments - CAR-T and CDX. What else do you think they should have announced? Do you seriously believe that a few people on this board or twitter can negatively or positively influence the stock? I am puzzled.
@Brewsky You may very well be right. I do not think you are though. The company had demonstrated its resilience and ingenuity in the past. Only time will tell…
@7*******s Do you think that it would be better for them to not spend any money, do nothing but generate a steady news flow? It seems to me that they have overachieved by far already given the total amount of money they spent.
What do you think a top ranking CEO would have done in this case?
March, as far as I understand.
They cannot file a full IND before all manufacturing is completed and their system of CAR-T production in the new facility is established and certified etc.
IND includes CMC section that needs to be complete. Without this FDA will never consent to the start of clinical trials.
I am happy with the RNS because it says precisely what I heard from other companies dealing with FDA. The Agency is overloaded, does not have sufficient bandwidth.
No fund manager will buy HEMO - it’s valuation is too low for any institutional investor. It has to be at least 100M to be considered.
You are spot on. Cellular component of immunity is the most enigmatic and the most difficult to implement though. HEMO is going to be a hero if they pull it off.
The management is playing a long game here. It looks like they are going into the clinic indeed.
The London market hates HEMO as much as it hates other biotech companies that have no revenue/profit. Look at PRTC. Puretech has multiple products in clinical trials, more than 400M in cash and is valued at barely 2.3x of its cash, just a bit better than HEMO. LSE is a grave for pre-revenue biotech companies. PRTC began transitioning to NASDAQ and that is likely the path HEMO will choose in due time. Such transition, rather than the news about CDX, lupus or CAR-T will make all HEMO shareholders 10-20 times richer.
As for the date of the CDX deal, it will most likely happen or not happen by mid October. We may also get another extension if they are not done in two weeks or so.
It will be interesting to read their semi-annual report.
It should be published by the end of this month I think. Unfortunately, it will cover the period before the end of June unless they include post-period description.
Someone smart with a longer investment horizon is gradually building their position.
@JHFH I think it is good that the market does not care about his tweets. It is actually great that you and I understand what the “market” does not.
@JHFH I think that my name is my choice and my problem. I personally would not start an acquaintance by immediately criticizing… As for releasing the name of the company HEMO is choosing or have chosen for manufacturing of their cells, then how do we know they signed an agreement already and how do we know if that company agreed to be named. Aren’t we still struggling with the GlobalCo identity?
You may be right that I should not look at Vlad’s Twitter but the message about Amgen is so transparent!
This site removed the link in my previous post. I was writing about the Amgen’s clinical trial termination. Amgen stoped clinical trials of their AMG427 bispecific antibody. That was a direct competitor of HEMO CDX. HEMO is a leader again!
@dhub What monthly updates do you expect? Do you want them to report that they evaluated five companies with their names as candidates for some sort of manufacturing? Do you expect them to report how many tests they conducted in the lab?
Look at their updates:
https://hemogenyx.com/investors/announcements
It is about twice a months with most that are substantial - advisor, presentation, patent etc.
Instead of fighting each other, you all better read what Vlad wrote on his Twitter.
He gave you all the most important update that is impossible to give using an RNS.
https://twitter.com/vmsandler/status/1424657262350635009
Have you tried to understand it?
Why do you all attack each other?
What updates are you waiting for? How often do you think a company like HEMO can issue updates? If I am not mistaken, they are developing drugs. Drug development is complicated and takes time. It takes months and years and a ... load of money.